TITLE

Precautionary Principles

AUTHOR(S)
Corneliussen, Filippa
PUB. DATE
May 2006
SOURCE
European Pharmaceutical Executive;May/Jun2006, p58
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on need for the biopharmaceutical industry to examine the oversight framework to regulate biomedical research and development activities in the private sector and to address how these laws and regulations affecting individual companies differ depending on the specific research being conducted and on the country where the company is located. The industry also need to provide details of the structures and processes that biomedical companies have put in place to implement the various laws and regulations relating to biomedical research and development activities in the private sector.
ACCESSION #
21057371

 

Related Articles

  • Biotech News Round-up.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p37 

    The article offers news briefs related to biotechnological developments. The phase III study of Amgen Inc. shows that anemia drug Aranesp produced a higher death rate compared to placebo. The phase III data of Schwarz Pharma shows that rotigotine has offered a statistically significant and...

  • Taking the Trial Out of Clinical Outsourcing. Hoffman, Joel // Bio-IT World;Apr2004, Vol. 3 Issue 4, p66 

    Discusses the elimination of clinical trials in clinical outsourcing. Cost of clinical trials for drug development; Key to managing relationship with selected outsourcing partners; Importance of communication to the success of projects; Factors that influence building and maintenance of the...

  • Phase 0 clinical trial - an overview. Satija, Aanchal // International Journal of Students' Research;Sep2011, Vol. 1 Issue 3, p76 

    Drug discovery begins in the laboratory with target identification and validation followed by pre-clinical and clinical development. The entire process takes around 10 to 15 years. It is associated with high costs and a high rate of failure. The probability of a drug going beyond Phase I testing...

  • Leaving the bench for the clinic. Frantz, Simon // Nature Reviews Drug Discovery;Apr2004, Vol. 3 Issue 4, p371 

    The increased demands on Clinical Research Associates mean that inexperienced applicants from academia should learn more about the clinical development process.

  • Measurement is Strategic. Paty, Jean // Applied Clinical Trials;Oct2010, Vol. 19 Issue 10, Special section p6 

    The article focuses on the significance of strategic measurement in evaluating the efficacy of products in clinical research. It stresses the need for pharmaceutical companies to provide evidence that any and all of the instruments used in the clinical trials were right for the task. Moreover,...

  • Medicine's MAGIC Bullets? Lenzer, Jeanne // Discover;Jul2008, Vol. 29 Issue 7, p46 

    This article discusses how drugs that are presumed to be medical miracles can also have lethal consequences for patients who have adverse reactions. Medical studies on drugs can be misleading and can also be misinterpreted by doctors and the public alike. Additionally, the increase of new...

  • Caution When Traveling Full Speed Ahead. Kaylynn Chiarello-Ebner // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p16 

    The author reflects on the implications of accelerated drug trials among pharmaceutical companies. She focuses on the disadvantage of the process wherein due to the being on fast track there is less time to scale up and fine tune the product, which is a key factor in drug development. She also...

  • Pfizer: new fears over Neurontin safety.  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p19 

    The article reports that Food and Drug Administration (FDA) has required makers of epilepsy drugs to re-examine clinical trial data in response to claims that Pfizer's Neurontin increases the risk of suicide. The FDA's request was a result of petition filed by attorney Andrew Finkelstein. Pfizer...

  • Data Monitoring Committees in Practice. Kerr, David; McBride, Ruth; Shemanski, Lynn // Applied Clinical Trials;Mar2004, Vol. 13 Issue 3, p42 

    Provides information about data monitoring committees DMC) and clinical trials in the U.S. Role of DMC; Reference to the draft guidance published by the Food and Drug Administration for deciding the need of the DMC in clinical trials; Scenarios under which a DMC might recommend stopping a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics